An Alzheimer’s treatment from Eli Lilly and Co. failed to slow memory decline in two separate patient studies, but the drug did show some potential to help in mild cases.
The Indianapolis drugmaker’s announcement could be a step toward a long-awaited breakthrough in the fight against the disease. But researchers not tied to the studies – and Eli Lilly itself – cautioned against overreacting to the initial results on the treatment, solanezumab.
News Tribune news services


JOIN THE DISCUSSION | Register here
We welcome comments. Please keep them civil, short and to the point. ALL CAPS, spam, obscene, profane, abusive and off topic comments will be deleted. Repeat offenders will be blocked. Thanks for taking part — and abiding by these simple rules. A thorough explanation of rules of conduct can be found in our Terms of Service. If you have any questions, including why your comment may not be showing immediately after you submit it, be sure to visit the commenting FAQ.